Small Interfering RNA Market size was valued at USD 14.97 billion in 2024 and is likely to cross USD 117.84 billion by 2037, expanding at more than 17.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of small interfering RNA is estimated at USD 17.03 billion. The reason behind the growth is impelled by rising cases of cancer across the globe. Small interfering RNA has been studied as an effective treatment for cancer as it targets specific mRNA and blocks abnormal gene expression that causes the disease. By 2040, there will be more than 26 million new instances of cancer worldwide.
The growing partnerships and collaborations are believed to fuel the market growth. For instance, in 2022 Alnylam Pharmaceuticals and Novartis came together to treat liver disease by using siRNA to suppress a Novartis-discovered target, which could lead to the regeneration of functional liver cells and advance the possibility for new drugs in a variety of illness conditions.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
17.2% |
|
Base Year Market Size (2024) |
USD 14.97 billion |
|
Forecast Year Market Size (2037) |
USD 117.84 billion |
|
Regional Scope |
|
Type (Liposome Based Systemic Therapy, Nanoparticle Based Systemic Therapy)
The liposome based systemic therapy segment is estimated to account for 53% share of the global small interfering RNA market during the forecast period. Liposomes offer several advantages as a siRNA delivery system owing to their ability to improve the delivery of antigens and other stimulatory molecules to antigen-presenting cells or T cells. Moreover, liposomes can selectively transport medications to the tumor, can be utilized to deliver specific medications to specific cell types to improve anti-tumor immune responses, and are known to be good carriers for drug delivery in conjunction with other therapies such as chemotherapy, radiation, and phototherapy.
Besides this, clinically proven liposomes are effective against pancreatic cancer as the only liposomal formulation currently licensed for the treatment of metastatic pancreatic cancer is nanoliposomal irinotecan (Onivyde) which was approved by the U.S. Food and Drug Administration (FDA) in 2022.
Indication (Cardiovascular Diseases, Respiratory Diseases, Oncology, Neurodegenerative Diseases, Infectious Diseases)
SiRNA market from the oncology segment is set to garner a notable share of 39% shortly. SiRNA is one of the most essential therapeutic approaches for treating a variety of genetic disorders, including cancer since it has shown promise in the treatment of several malignancies, including breast and prostate cancer. To target cancer, siRNA can be supplied to the entire organism or to a specific tissue which will aid in reducing the expression of various multidrug-resistant genes in cancer cells.
End-User (Hospital, Research Institutions, Pharmaceutical and Biotechnology Companies, Academic Institutions)
The research institutions segment is set to garner significant share of 44% during the forecast timeframe. SiRNA has recently been used in therapeutic applications and is now a potent method for studying gene function in research institutions that can be employed both in vitro and in vivo. Moreover, their use aids in the development of novel techniques to reduce off-target effects brought on by detrimental protein binding or unwanted targeting of mRNA in addition to assist researchers in better understanding the process of gene silence.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
End-User |
|
|
Indication |
|
North American Market Forecast
Small Interfering RNA market in North America is predicted to account for the largest share of 37% by 2037 impelled by the increasing spending in healthcare. This has led to the development of efficient and effective therapies for small interfering RNA in the region. Besides this, as a consequence, many academic institutions including Harvard University and the University of California, San Francisco (UCSF) have started researching small interfering RNA. For instance, at the UNIVERSITY OF CALIFORNIA, RIVERSIDE two scientists Shou-wei Ding and Shabihah Shahrudin identified in a recent research that a novel Dicer enzyme isoform a protein that functions similarly to another protein, protects mouse and for human stem cell treatment from RNA viruses which could significantly enhance siRNA therapeutics to treat SARS-CoV-2. According to estimates, in 2021, healthcare spending in the United States increased by more than 2% to roughly USD 4 trillion.
APAC Market Statistics
The APAC Small Interfering RNA market is estimated to be the second largest, during the forecast timeframe led by growing advancements in biotechnology. In recent years, India's biotechnology industry has risen quickly owing to increased economic prosperity and health consciousness, which has led to significant progress in the development of siRNA therapies for the treatment of a variety of disease targets, including viral infections and cancer.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?